$6.90
-0.04 (-0.58%)
Open$6.96
Previous Close$6.94
Day High$7.12
Day Low$6.83
52W High$12.58
52W Low$6.32
Volume—
Avg Volume26.8K
Market Cap28.34M
P/E Ratio0.15
EPS$45.30
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+362.5% upside
Current
$6.90
$6.90
Target
$31.91
$31.91
$24.67
$31.91 avg
$44.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.47M | 18.08M | 5.44M |
| Net Income | 184.26M | 463.60M | -1,283,535 |
| Profit Margin | 2,848.6% | 2,706.2% | -23.6% |
| EBITDA | -51,956,993 | -137,990,336 | -2,024,078 |
| Free Cash Flow | — | — | -1,099,827 |
| Rev Growth | -64.2% | -64.2% | +18.0% |
| Debt/Equity | 0.08 | 0.08 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |